Helicobacter therapeutic

Abstract

The present invention relates to method of treating and/or preventing inflammation in a subject caused by bacteria that express HtrA. The present invention further relates to immunogenic compositions comprising an HtrA polypeptide or fragment thereof, as well as a therapeutic and/or prophylactic vaccine for treating or preventing disease.

1 . A method of treating or preventing bacteria induced inflammation in a subject, the method comprising administering to the subject a bacterial HtrA polypeptide or fragment thereof of at least 10 amino acids, and/or an antibody that binds bacterial HtrA. 
     
     
         2 . The method of  claim 1 , wherein the method comprises administering an immunogenic composition comprising a bacterial HtrA polypeptide or fragment thereof of at least 10 amino acids. 
     
     
         3 . The method of  claim 1 , wherein the inflammation is induced by  Helicobacter pylori  and the HtrA polypeptide is a  Helicobacter pylori  HtrA polypeptide or fragment thereof of at least 10 amino acids. 
     
     
         4 . The method of  claim 1 , wherein the HtrA polypeptide or fragment thereof of at least 10 amino acids comprises an amino acid sequence at least 95% identical to any one of SEQ ID NOs:1-6 or to a fragment thereof of at least 10 amino acids. 
     
     
         5 . The method of  claim 1 , wherein the bacteria induced inflammation is gastritis and/or duodenitis. 
     
     
         6 . (canceled) 
     
     
         7 . An immunogenic composition and/or pharmaceutical comprising a bacterial HtrA polypeptide or a fragment thereof of at least 10 amino acids, and/or an antibody that binds bacterial HtrA. 
     
     
         8 . (canceled) 
     
     
         9 . The immunogenic composition and/or pharmaceutical of  claim 7 , wherein the bacterial HtrA polypeptide or fragment thereof of at least 10 amino acids is a  Helicobacter pylori  polypeptide or fragment of at least 10 amino acids thereof. 
     
     
         10 . The immunogenic and/or pharmaceutical composition of  claim 7 , wherein the composition comprises an HtrA polypeptide comprising an amino acid sequence at least 95% identical to any one of SEQ ID NOs:1-6 or a fragment thereof of at least 10 amino acids. 
     
     
         11 . The immunogenic and/or pharmaceutical composition of  claim 7  comprising a pharmaceutically acceptable excipient and/or adjuvant. 
     
     
         12 . The immunogenic and/or pharmaceutical composition of  claim 11  which is a vaccine. 
     
     
         13 . The immunogenic composition and/or pharmaceutical of  claim 12  which is a therapeutic vaccine. 
     
     
         14 . (canceled) 
     
     
         15 . The immunogenic and/or pharmaceutical composition of  claim 14 , wherein the antibody binds  Helicobacter pylori  HtrA polypeptide. 
     
     
         16 . The pharmaceutical composition of  claim 14  or  claim 15 , wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanised antibody, a human antibody, Fab, F(ab′) 2 , or an scFv. 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . The immunogenic composition of  claim 7 , wherein the bacteria induced inflammation is  Helicobacier pylori  induced inflammation. 
     
     
         20 . The immunogenic composition of  claim 19 , wherein the bacteria induced inflammation is gastritis and/or duodenitis. 
     
     
         21 . The immunogenic composition of  claim 20 , wherein the inflammation is atrophic gastritis. 
     
     
         22 .- 25 . (canceled) 
     
     
         26 . A method of treating or preventing a disease caused by  Helicobacter pylori  infection in a subject, the method comprising administering to the subject an HtrA polypeptide or fragment thereof of at least 10 amino acids. 
     
     
         26 . (canceled) 
     
     
         27 . The method of  claim 26 , wherein the HtrA polypeptide comprises an amino sequence at least 95% identical to any one of SEQ ID NOs:1-6 or a fragment thereof of at least 10 amino acids. 
     
     
         28 . (canceled) 
     
     
         29 . The method of  claim 26 , wherein the disease caused by  Helicobacter pylori  infection is inflammation, gastritis, gastric ulcer, duodenal ulcer, gastric cancer, and/or mucosa-associated-lymphoid-tissue (MALT) lymphoma. 
     
     
         30 . The method of  claim 26 , wherein the method comprises administering to the subject an immunogenic and/or pharmaceutical composition comprising an HtrA polypeptide or fragment thereof of at least 10 amino acids.